The study, sponsored by the University of Bern, aims to explore the relationship between VOCs and blood glucose levels in Type 1 Diabetes patients during induced hypoglycaemic episodes. This research could lead to innovative non-invasive monitoring technologies for diabetes management, potentially positioning the BreathSpec® device as a novel tool in the diabetes care market. Given the increasing prevalence of diabetes globally, advancements in monitoring technologies could capture significant market interest. However, the competitive landscape includes established glucose monitoring devices and continuous glucose monitoring (CGM) systems, necessitating a clear differentiation strategy for any resultant product. The study's completion in July 2024 may provide critical data for future commercialization efforts.